ImmunoForge is a clinical-stage, venture-backed company specializing in novel drug development based on ELP platform technology, powered by world-class expertise and focusing initially on muscular dystrophies such as Polymyositis (PM), Dermatomyositis (DM), Duchenne muscular dystrophy (DMD) and Senile Sarcopenia. ImmunoForge is conducting a Phase 2 clinical study for its lead drug candidate PF1801 for treatment of DM/PM and PF1804 got IND approval from the US FDA for Phase 2 of DMD cardiomyopathy and is ready to begin Phase 2 study looking for co-development or licensing partners.